Cabozantinib in Combination With Atezolizumab for Advanced Renal Cell Carcinoma: Results From the COSMIC-021 Study.
Sumanta Kumar PalBradley Alexander McGregorCristina SuárezChe-Kai TsaoWilliam KellyUlka N VaishampayanLance PagliaroBenjamin L MaughanYohann LoriotDaniel CastellanoSandy SrinivasRana R McKayRobert DreicerThomas E HutsonSarita DubeyScott WernekeAshok PanneerselvamDominic CurranChristian ScheffoldToni K ChoueiriArchana M AgarwalPublished in: Journal of clinical oncology : official journal of the American Society of Clinical Oncology (2021)
The novel combination of cabozantinib plus atezolizumab demonstrated encouraging clinical activity and acceptable tolerability in patients with advanced ccRCC and nccRCC. Disease control was observed across dose levels and histologic subtypes.